cediranib plus olaparib significantly increases pfs in recurrent ovarian cancer
Published 10 years ago • 189 plays • Length 4:52Download video MP4
Download video MP3
Similar videos
-
4:19
cediranib plus olaparib increases progression-free survival in recurrent ovarian cancer
-
1:38
dr. liu on cediranib/olaparib in recurrent ovarian cancer
-
2:13
dr. patel on cediranib versus olaparib in recurrent platinum-sensitive ovarian cancer
-
2:12
dr. patel on an analysis of olaparib and cediranib for ovarian cancer
-
0:54
dr. ursula matulonis on phase iii trials examining cediranib plus olaparib in ovarian cancer
-
3:24
solo-1: olaparib or placebo for patients with newly diagnosed brca-mutated advanced ovarian cancer
-
0:55
a study of olaparib and cediranib in ovarian cancer
-
0:53
dr. annunziata on olaparib and cediranib combination in ovarian cancer
-
6:49
olaparib with or w/out cediranib vs standard of care for recurrent platinum-sensitive ovarian cancer
-
5:15
adding cediranib to chemo improves pfs for metastatic cervical cancer
-
1:29
significant factors of clinical outcomes with olaparib in patients with ovarian cancer
-
6:53
treatment sequencing in advanced ovarian cancer
-
7:38
results from phiii solo1 trial in brcam ovarian cancer
-
5:40
parp inhibitor combo shows early promise for patients with and without brca mutations
-
2:48
rationale for olaparib in advanced ovarian cancer
-
4:25
gynecologic oncology at esmo congress 2021: randomised phase ii trial of olaparib
-
5:53
current treatment standards for primary ovarian cancer
-
10:49
prognosis of r/r dlbcl